Study of AMG 732 Injection for Adults With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

What this Trial Is About

This trial is designed to evaluate the effectiveness of AMG 732 in adults with thyroid eye disease TED who either did not respond initially or experienced a relapse during safety follow-up in an earlier Amgen-sponsored trial. The study focuses on participants previously enrolled in AMG 732 studies who have moderate-to-severe TED and are seeking treatment options beyond surgery or irradiation. Participants will receive AMG 732 through subcutaneous injections. This open-label, single-group study involves a treatment period lasting up to 24 weeks, during which participants will be monitored for changes in proptosis eye bulging and drug levels in the body. The trial also tracks safety events up to 48 weeks after treatment begins. Throughout the study, participants will undergo assessments including proptosis measurement using an exophthalmometer, and laboratory tests to monitor AMG 732 concentrations and safety. Researchers will evaluate eye response and adverse events to understand how the drug performs in people who previously did not respond or relapsed. The total participation period extends to approximately 48 weeks to capture treatment effects and safety outcomes.

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease